EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Next‐Generation Immunotherapies for Pseudomonas aeruginosa : Monoclonal Antibodies and Immune Checkpoint Modulation

Muhammad Shahid Mehmood iD, Taimoor Wajid iD, Muhammad Saleem iD, Rida Khalid, Muhammad Husnain Mumtaz iD

APMIS · 2026-11 · 134 (11)

DOI: 10.1111/apm.70275 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift APMIS, online erschienen am 26.10.2026. Verfasst von Muhammad Shahid Mehmood und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Microbiology, University of Agriculture Faisalabad, Faisalabad, Pakistan. Hauptthemen laut MEDLINE: Immunotherapy, Antibodies, Monoclonal, Pseudomonas aeruginosa, Pseudomonas Infections. Die Arbeit nennt 94 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Pseudomonas aeruginosa represents a critical healthcare challenge, accounting for 7%–10% of hospital‐acquired infections globally, with particularly high prevalence in intensive care, burn, and respiratory units, alongside escalating rates of multidrug‐resistant and extensively drug‐resistant strains. The bacterium evades host immunity through multiple mechanisms, including Type III Secretion System effector translocation and biofilm formation via polysaccharide matrices (alginate, Psl, Pel). Antibiotic‐based therapies are increasingly ineffective, necessitating host‐directed immunotherapeutic strategies. This review synthesizes emerging evidence on monoclonal antibody therapy and immune checkpoint modulation for P. aeruginosa infections. Bispecific antibodies targeting PcrV and Psl enhance opsonophagocytic killing and biofilm disruption through Fc‐mediated mechanisms. Immune checkpoint inhibitors (anti‐PD‐1/PD‐L1) reverse T‐cell exhaustion from chronic antigen exposure and LPS‐driven upregulation of inhibitory receptors, restoring antimicrobial function. Combination approaches integrating mAbs with antibiotics and checkpoint blockade show potential for synergistic bacterial clearance in preclinical pneumonia and burn wound models. Clinical translation remains limited by antigen variability (Psl and PcrV epitope polymorphisms), biofilm heterogeneity, and host immunogenetic diversity (Fc receptor polymorphisms, HLA variants, cytokine profiles). Multi‐omics profiling may enable personalized treatment selection. Safety concerns regarding immune hyperactivation require carefully dosed, biomarker‐guided strategies. Future development demands genomic stratification of responders and optimized therapeutic windows for maximal clinical benefit.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ImmunotherapyAntibodies, MonoclonalPseudomonas aeruginosaPseudomonas InfectionsImmune Checkpoint InhibitorsHumansAnimalsBiofilmsHost-Directed Therapy

Stichwörter der Autor:innen

PD‐1/PD‐L1 axisPseudomonas aeruginosa MDRT3SS and biofilm tolerancemonoclonal immunotherapy

Substanzen

Antibodies, MonoclonalImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Institute of Microbiology, University of Agriculture Faisalabad, Faisalabad, Pakistan.
  • King Edward Medical University, Lahore, Pakistan.
  • Kohsar University Murree, Murree, Pakistan.
  • National University of Sciences and Technology, Islamabad, Pakistan.
  • Allama Iqbal Medical College, Lahore, Pakistan.

ORCID-Profile: Muhammad Shahid Mehmood, Taimoor Wajid, Muhammad Saleem, Muhammad Husnain Mumtaz

Zitieren

APA

Mehmood, M. S., Wajid, T., Saleem, M., Khalid, R., & Mumtaz, M. H. (2026). Next‐Generation Immunotherapies for Pseudomonas aeruginosa : Monoclonal Antibodies and Immune Checkpoint Modulation. APMIS, 134(11). https://doi.org/10.1111/apm.70275

Vancouver

Mehmood MS, Wajid T, Saleem M, Khalid R, Mumtaz MH. Next‐Generation Immunotherapies for Pseudomonas aeruginosa : Monoclonal Antibodies and Immune Checkpoint Modulation. APMIS. 2026;134(11). doi:10.1111/apm.70275

BibTeX
@article{Mehmood2026,
  author = {Mehmood, Muhammad Shahid and Wajid, Taimoor and Saleem, Muhammad and Khalid, Rida and Mumtaz, Muhammad Husnain},
  title = {Next‐Generation Immunotherapies for Pseudomonas aeruginosa : Monoclonal Antibodies and Immune Checkpoint Modulation},
  journal = {APMIS},
  year = {2026},
  volume = {134},
  number = {11},
  doi = {10.1111/apm.70275}
}
Kostenlos starten →